ALK and non-small cell lung carcinoma: A comprehensive genomic profiling of 3035 NSCLC BM cases versus unmatched primary tumors showed higher rates of several targetable genetic alternations in BMs compared to primary sites, including ALK fusion, KRASG12C mutations and MET amplifications [66].